Hypoglycemia induced by long-acting somatostatin analogues in a patient with nonfunctional neuroendocrine tumor

Abstract

Somatostatin and its long-acting analogues are effective in symptom control in patients with functional neuroendocrine tumors; they are also able to control tumor growth. Somatostatin analogues are safe and generally well tolerated. In some cases they may cause serious complications